What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Atrial fibrillation
- Cardiology
Michael D. Ezekowitz mainly focuses on Atrial fibrillation, Dabigatran, Warfarin, Stroke and Anesthesia.
Internal medicine and Cardiology are closely tied to his Atrial fibrillation research.
Michael D. Ezekowitz has researched Cardiology in several fields, including Hazard ratio and Confidence interval.
His work on Idarucizumab as part of general Dabigatran research is frequently linked to Text messaging, bridging the gap between disciplines.
His Warfarin study integrates concerns from other disciplines, such as Cardioversion and Myocardial infarction.
His Stroke research focuses on Cerebral infarction in particular.
His most cited work include:
- Dabigatran versus warfarin in patients with atrial fibrillation (7970 citations)
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society (5388 citations)
- Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (3624 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Atrial fibrillation, Cardiology, Stroke and Warfarin.
In his study, Antithrombotic is strongly linked to Intensive care medicine, which falls under the umbrella field of Atrial fibrillation.
His Cardiology research includes elements of Subgroup analysis and Confidence interval.
His work carried out in the field of Stroke brings together such families of science as Embolism, Vitamin K antagonist, Clopidogrel, Apixaban and Risk factor.
The study incorporates disciplines such as Anticoagulant, Randomized controlled trial, Surgery and Anesthesia in addition to Warfarin.
His study on Direct thrombin inhibitor is often connected to Discovery and development of direct thrombin inhibitors as part of broader study in Dabigatran.
He most often published in these fields:
- Internal medicine (76.88%)
- Atrial fibrillation (69.35%)
- Cardiology (60.30%)
What were the highlights of his more recent work (between 2015-2021)?
- Atrial fibrillation (69.35%)
- Internal medicine (76.88%)
- Cardiology (60.30%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Atrial fibrillation, Internal medicine, Cardiology, Stroke and Warfarin.
His work deals with themes such as Myocardial infarction and Intensive care medicine, which intersect with Atrial fibrillation.
His Cardiology study combines topics in areas such as Diabetes mellitus and Left ventricular hypertrophy.
His research integrates issues of Incidence, Atrial flutter, Heart failure, Risk of mortality and Apixaban in his study of Stroke.
He is involved in the study of Warfarin that focuses on Dabigatran in particular.
The Dabigatran study combines topics in areas such as Surgery, Apolipoprotein A1, Lipoprotein metabolism, Apolipoprotein B and Hematology.
Between 2015 and 2021, his most popular works were:
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society (807 citations)
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons (584 citations)
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (235 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cardiology
- Myocardial infarction
His main research concerns Atrial fibrillation, Cardiology, Internal medicine, Stroke and Warfarin.
He has researched Atrial fibrillation in several fields, including Risk factor and Intensive care medicine.
Within one scientific family, Michael D. Ezekowitz focuses on topics pertaining to Biomarker under Cardiology, and may sometimes address concerns connected to Framingham Risk Score, Apixaban and Proportional hazards model.
His work in the fields of Internal medicine, such as Electrocardiography, Sudden cardiac death and Heart Rhythm, intersects with other areas such as Benign early repolarization and Clinical Practice.
His Stroke study incorporates themes from Atrial flutter, Cohort study, Incidence, Heart failure and Quality of life.
Specifically, his work in Warfarin is concerned with the study of Dabigatran.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
